About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases1. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.
1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (link is external) (accessed Apr 2018)
Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control and to reduce the risk of cardiovascular death in patients with established cardiovascular disease.
Empagliflozin + Metformin HCl (Jardiance Duo®)
Empagliflozin + Metformin HCl (Jardiance Duo®) is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus:
- When treatment with both empagliflozin and metformin is appropriate
- Inadequately controlled with metformin or empagliflozin alone
- Inadequately controlled with empagliflozin or metformin in combination with other glucose lowering products including insulin
- Already treated with empagliflozin and metformin co-administered as separate tablets.
Empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death.
Linagliptin (Trajenta®) is indicated in adults patients with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise, as monotherapy or as add-on to metformin, a sulphonylurea, insulin (with or without metformin) or metformin plus a sulphonylurea.
Linagliptin + Metformin HCl (Trajenta Duo®)
Linagliptin + Metformin HCl (Trajenta Duo®) is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.
Linagliptin + Metformin HCl (Trajenta Duo®) is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximum tolerated dose of metformin and a sulphonylurea.
Linagliptin + Metformin HCl (Trajenta Duo®) is indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin and metformin alone do not provide adequate glycaemic control.
Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).
1 Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.
Dabigatran etexilate (Pradaxa®)
Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Telmisartan (Micardis®) is an angiotensin receptor blocker (ARB) that is used in the treatment of essential hypertension. Micardis® 80mg once a day is also indicated for reduction of the risk of myocardial infarction, stroke or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events. High risk of cardiovascular events can be evidenced by history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage.
Telmisartan + HCTZ (Micardis Plus®)
As fixed dose combination Telmisartan + Hydrochlorothiazide (Micardis Plus®) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone. The maximum antihypertensive effect is generally attained with Micardis Plus® 4 – 8 weeks after the start of treatment.
Telmisartan + Amlodipine (Twynsta®)
Telmisartan + Amlodipine (Twynsta®) is used in the treatment of essential hypertension in adults.
As Replacement Therapy: Patients receiving telmisartan and amlodipine from separate tablets may instead receive Twynsta® containing the same component doses.
As Add on therapy: Twynsta® is indicated in patients whose blood pressure is not adequately controlled on telmisartan or amlodipine monotherapy.
As Initial therapy: Twynsta® may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Twynsta® as initial therapy for hypertension should be based on an assessment of potential benefits and risks.
Cancer takes. Takes away loved ones, time and invaluable milestones. At Boehringer Ingelheim we are providing new hope for patients by taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum based chemotherapy.1
1. GIOTRIF® Summary of Product Characteristics 2018
Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.
Tiotropium + Olodaterol (Spiolto® Respimat®)
Tiotropium + Olodaterol (Spiolto® Respimat®) is a once daily long-acting LAMA/LABA therapy of tiotropium 5 mcg (LAMA) and olodaterol 5 mcg (LABA), delivered via Respimat®. It is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Spiolto® Respimat® is administered as 2 puffs, once daily.1
1. Spiolto® Prescribing Information